Treatment
Sorafenib clinical trials
We’re tracking 20 recruiting studies that include Sorafenib, each written for real people, not researchers, below.
Recruiting studies
- NCT06592989Recruiting
Sorafenib and gefitinib for advanced pNET
This trial tests a combination of two targeted drugs (sorafenib and gefitinib) for people with pancreatic neuroendocrine tumors (pNETs) that have continued to grow after other treatments. The goal is to see if this combination can help control the tumor.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07463651RecruitingPhase 3
Gilteritini vs Sorafenib after transplant for FLT3-ITD AML
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
Suzhou, JiangsuAges 14–70 - NCT07787429RecruitingPhase 2
Comparing two treatments for high-risk bone cancer
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
Warsaw, MazovianAges 5 months–30 years - NCT06309485RecruitingPhase 2
Study of WGI-0301 for advanced liver cancer
This trial tests a new drug, WGI-0301, for people with advanced hepatocellular carcinoma (HCC, a type of liver cancer) that has progressed after standard treatments. It aims to see if WGI-0301 can help control the cancer when other options have stopped working or caused side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05468359RecruitingPhase 1/Phase 2
Testing four medicines in children and teens with hard-to-treat tumors
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
Germantown, TennesseeAges Up to 30 years - NCT06527495RecruitingPhase 1/Phase 2
Genetics of Sorafenib in Liver Cancer Patients
This trial tests whether the way your body processes the drug sorafenib (used for liver cancer) affects its safety and effectiveness. It aims to find the best dose for patients based on their genetics, which could lead to better treatment outcomes.
Shibīn al Kawm, MenoufiaAges 18–80 - NCT06532084RecruitingPhase 2
Sorafenib to prevent relapse after stem cell transplant
This trial tests whether the drug sorafenib can prevent blood cancer from returning after a stem cell transplant. It is for people who had a special combination of chemotherapy (bendamustine and cyclophosphamide) during their transplant and are at high risk for relapse.
Saint PetersburgAges 18–75 - NCT06482086RecruitingPhase 2
Using tumor models to guide drug choice for advanced thyroid cancer
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
Chengdu, SichuanAges 18 years+ - NCT06972641RecruitingPhase 2/Phase 3
Gene-based maintenance therapy after stem cell transplant
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 14–75 - NCT02029001RecruitingPhase 2
Personalized treatment matched to your tumor’s DNA changes
This Phase 2 study tests whether choosing cancer drugs based on specific DNA or blood test results from your tumor can work better for people with advanced solid tumors. It aims to use a molecular tumor board’s recommendation to guide the safest, most likely targeted treatment for each patient.
BordeauxAges 18 years+ - NCT03899428RecruitingPhase 2
Immune therapy versus targeted therapy for advanced liver cancer
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hong Kong, Hong Kong SARAges 18 years+ - NCT05594095RecruitingPhase 2
Study for advanced ER+ HER2− breast cancer after CDK4/6 therapy
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05669339RecruitingPhase 2
AI-guided dosing study for advanced liver cancer patients
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
Gainesville, FloridaAges 18–99 - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT05717738Recruiting
Immunotherapy plus targeted drugs after TACE for liver cancer
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Quanzhou, FujianAges 18 years+ - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT06690697RecruitingPhase 2
Toripalimab and JS004 for advanced kidney cancer
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07024680Recruiting
Sunitinib or sorafenib for papillary kidney cancer
This study looks at how well sunitinib or sorafenib work as a first treatment for a type of kidney cancer called papillary renal cell carcinoma (PRCC) that cannot be removed with surgery or has spread. It aims to understand real-world results in Chinese patients.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT02559778RecruitingPhase 2
Precision treatment trial for children with advanced neuroblastoma
This Phase 2 trial studies a targeted treatment approach for children and young adults with advanced neuroblastoma (a childhood cancer). It may help by using lab-tested cancer features to guide therapy after initial treatment and transplant.
Birmingham, AlabamaAges Up to 22 years - NCT07560566RecruitingPhase 2
Preventing Hand-Foot Skin Reaction in Liver Cancer Treatment
This study tests whether a topical anti-inflammatory cream (indomethacin) applied preventively to hands and feet can reduce a painful skin side effect called hand-foot syndrome that occurs in advanced liver cancer patients taking sorafenib. If effective, it could help patients tolerate their cancer medication better.
TaipeiAges 18 years+
What Sorafenib is being studied for
Conditions with recruiting Sorafenib studies.
Common questions
- Are there clinical trials studying Sorafenib?
- Yes. Clin2 currently lists 20 recruiting studies that include Sorafenib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sorafenib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sorafenib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sorafenib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.